We are pleased to announce that our partnership with Roche has been nominated for Scrip’s Best Partnership Alliance Award. This recognition celebrates our collaborative efforts to discover and develop molecular glue degraders for cancer and neurological diseases. We are proud of the innovation and teamwork that drives this journey and look forward to continuing our shared mission to explore novel therapeutic strategies and advance new treatment options for people living with difficult-to-treat conditions. https://bit.ly/3Y8vzej #ScripAwards #partnership
Monte Rosa Therapeutics
Biotechnology Research
Boston, Massachusetts 20,124 followers
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (M
About us
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. Monta Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology and proteomics to identify degradable protein targets and rationally design MGDs with unprecedented selectivity. The QuEEN™ discovery engine enables access to a wide-ranging and differentiated target space of well-validated biology across multiple therapeutic areas. Monte Rosa has developed the industry’s leading pipeline of MGDs.
- Website
-
http://www.monterosatx.com
External link for Monte Rosa Therapeutics
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Boston, Massachusetts
- Type
- Public Company
Locations
-
Primary
321 Harrison Ave
Suite 900
Boston, Massachusetts 02118, US
-
Klybeckstrasse 191
WKL 136.3
Basel, 4057, CH
Employees at Monte Rosa Therapeutics
Updates
-
Thank you to Pinkergreen for capturing the fun and creative side of our company! It is a joy to work with the amazing people at Monte Rosa as we develop highly selective MGD medicines for patients! Learn more about our science and culture on our recently launched website; www.monterosatx.com !
Still one of my favorite BTS moments on Monte Rosa Therapeutics new website, and 1000% my favorite corporate headshots we've ever done.
-
We are thrilled to announce the launch of our new website! You can find the new site at www.monterosatx.com ! Great People Fuel Great Science! We had a wonderful team to create a website that tells our story. Thank you to the many Monte Rosa employees that helped, to the fabulous design team at Pinkergreen and to Brett Clair and Tatjana Hirschmugl for your amazing graphics.
-
Today we presented exciting preclinical data on our development candidate MRT-8102, demonstrating that it’s a potent, selective, and durable molecular glue degrader (MGD) of NEK7. The data provide preclinical proof of concept that a NEK7 MGD leads to inhibition of the NLRP3 inflammasome and IL-1 release to reduce the effects of inflammation, supporting the potential to address central and peripheral inflammatory disorders. https://bit.ly/4d18243
-
Inspired by the 2024 Olympics, Monte Rosa held a fun filled competition where we showcased hidden talents and shared the biggest laughs. #Olympics #Competition
-
What a great day supporting the Mission of Science Club for Girls! Learn more about their amazing mission. #girlsinSTEM, #ScienceClubForGirls
-
Today we announce the initiation of our Phase 1 clinical study of MRT-6160, a potent, highly selective, and orally bioavailable VAV1-directed MGD, which we believe is the first rationally designed MGD in clinical development for a non-oncology indication. Learn more here: https://bit.ly/3MbgD9C
-
Are you attending #ACSFall2024? Join Bernhard Fasching's talk as he explains how we use rational design of molecular glue degraders to expand the CRBN target space. #molecularglues